ALXNUnknown
ALEXION PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for ALEXION PHARMACEUTICALS, INC. (ALXN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ALXN insiders buying or selling?
ALEXION PHARMACEUTICALS, INC. insiders reported 3 open-market buys ($40.7M) and 14 sells ($45.0M) across 17 Form 4 filings — a net selling position of $4.3M.
Source: SEC EDGAR Form 4
Key Statistics (as of Dec 21, 2020)
Total Form 4 filings
17
SEC EDGAR
Insider filers
11
Insider buys (3)
$40.7M
Insider sells (14)
$45.0M
Insider sentiment
Net sellingNet insider flow of $4.3M in net selling.
Recent ALXN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 21, 2020 | Daniel Bazarko | SVP, Controller, CAO | Sale | 24.1K | $157.70 | $3.8M |
| Dec 4, 2020 | Tanisha Carino | EVP & CCAO | Sale | 1.5K | $122.26 | $187.1K |
| Jun 9, 2020 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 6.9K | $114.69 | $786.0K |
| Mar 18, 2020 | Felix Baker | Director | Purchase | 81.4K | $82.01 | $6.7M |
| Mar 18, 2020 | Felix Baker | Director | Purchase | 418.6K | $78.33 | $32.8M |
| Jul 2, 2019 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 4.5K | $132.78 | $597.5K |
| Jun 24, 2019 | Aradhana Sarin | Chief Strategy & Business Off | Sale | 578 | $132.00 | $76.3K |
| May 30, 2019 | Felix Baker | Director | Sale | 300.0K | $123.74 | $37.1M |
| Feb 20, 2019 | Daniel Bazarko | SVP, Controller, CAO | Sale | 2.0K | $126.00 | $252.0K |
| Jan 3, 2019 | Ludwig Hantson | CEO | Sale | 3.2K | $95.85 | $310.9K |
| Nov 30, 2018 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 2.6K | $118.13 | $307.7K |
| Jul 12, 2018 | Paul J Clancy | EVP, Chief Financial Officer | Sale | 5.2K | $131.11 | $687.1K |
| Jun 12, 2018 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 1.5K | $118.53 | $173.8K |
| Jun 12, 2018 | Anne-Marie Law | EVP and CHRO | Sale | 1.9K | $118.53 | $220.7K |
| Jun 12, 2018 | Brian Goff | EVP & Chief Commercial Officer | Sale | 1.6K | $118.53 | $195.0K |
| Jun 12, 2018 | John J Orloff | EVP, Research & Development | Sale | 2.1K | $118.53 | $250.7K |
| May 2, 2018 | COUGHLIN CHRISTOPHER J | Director | Purchase | 10.0K | $120.79 | $1.2M |
Showing the 17 most recent of 17 Form 4 filings for ALEXION PHARMACEUTICALS, INC..
Most active ALXN insiders
- Indrani Lall Franchini4 filings
- Felix Baker3 filings
- Daniel Bazarko2 filings
- Anne-Marie Law1 filing
- Aradhana Sarin1 filing
Ask anything about ALXN insider activity
Use Trabud's AI agent to query ALEXION PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me ALXN CEO purchases this year" or compare it against any other ticker.
Open the AI agentALXN insider trading FAQ
Are ALEXION PHARMACEUTICALS, INC. insiders buying or selling?
Across 17 SEC Form 4 filings, ALEXION PHARMACEUTICALS, INC. (ALXN) insiders reported 3 open-market purchases totaling $40.7M and 14 sales totaling $45.0M. That is a net selling position of $4.3M.
How many insiders trade ALXN stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ALEXION PHARMACEUTICALS, INC.. The most recent filing was accepted on Dec 21, 2020.
Where does Trabud get ALXN insider trading data?
All ALXN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.